New Visterra antibody broadly neutralizes dengue virus in studies
VIS513 works by binding and neutralizing all four dengue virus serotypes. It successfully protected mice that received a lethal dose of dengue virus. The data shows that VIS513 has positive results as a single administration treatment for the infections.
Visterra applies its proprietary technology platform to discover unique disease targets and create new therapeutics for infectious diseases. VIS513 is its latest development, a novel monoclonal antibody that is designed to treat dengue.
The published article, “Structure-Guided Design of an Anti-Dengue Antibody Directed to a Non-Immunodominant Epitope,” provides details of the preclinical data. Scientists united from Duke-National University of Singapore, Massachusetts Institute of Technology, Nanyang Technological University, and the Singapore-MIT Alliance for Research and Technology (SMART) Center to conduct the research.
“Dengue is the most common mosquito-transmitted viral disease in the world, currently with no specific treatment, and prevention solely dependent on effective vector control measures,” Zach Shriver, vice president of research at Visterra, said. “We are very encouraged by the ability of a single administration of VIS513 to rapidly reduce and virtually eliminate viremia, and mitigate symptoms of severe dengue infection in multiple mouse models. These new preclinical data further demonstrate the potential of VIS513 to effectively neutralize across all four dengue virus serotypes and provide additional support for Visterra’s plans to advance VIS513 into clinical development.”